Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Kleiner Perkins
Deal Size : $130.0 million
Deal Type : Series B Financing
NewLimit Raises $130M to Push Liver mRNA Med Into Clinic
Details : The proceeds will be used to push a liver-rejuvenating mRNA medicine into clinic. The preclinical asset uses lipid nanoparticles to deliver mRNA to liver cells that codes for transcription factors.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
May 06, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Kleiner Perkins
Deal Size : $130.0 million
Deal Type : Series B Financing